Tobacco Companies Reach Settlement With Texas for $15.3 Billion

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 7 No 2
Volume 7
Issue 2

TEXARKANA, Tex-The tobacco industry has reached a settlement with the State of Texas worth $15.3 billion, the largest such settlement to date. Previously, the companies settled with Mississippi for $3.4 billion and with Florida for $11.3 billion. The state’s private trial lawyers will receive 15% of the sum in fees, a total of more than $2.2 billion.

TEXARKANA, Tex—The tobacco industry has reached a settlement with the State of Texas worth $15.3 billion, the largest such settlement to date. Previously, the companies settled with Mississippi for $3.4 billion and with Florida for $11.3 billion. The state’s private trial lawyers will receive 15% of the sum in fees, a total of more than $2.2 billion.

The settlement is to reimburse the state for Medicaid money spent to treat people with smoking-related illnesses. The money is earmarked for state antismoking campaigns, but Texas lawmakers have said that only the Legislature has the authority to decide how to spend state funds.

Although the settlement perhaps helps clear the way for Congress to consider the proposed $368.5 billion agreement between the companies and more than 40 state attorneys general, another trial is looming in Minnesota, where attorney general Hubert Humphrey III has vowed to make the companies pay heavily.

Recent Videos
Educating community practices on CAR T referral and sequencing treatment strategies may help increase CAR T utilization.
The FirstLook liquid biopsy, when used as an adjunct to low-dose CT, may help to address the unmet need of low lung cancer screening utilization.
An 80% sensitivity for lung cancer was observed with the liquid biopsy, with high sensitivity observed for early-stage disease, as well.
9 Experts are featured in this series.
9 Experts are featured in this series.
Harmonizing protocols across the health care system may bolster the feasibility of giving bispecifics to those with lymphoma in a community setting.
2 experts are featured in this series.
Patients who face smoking stigma, perceive a lack of insurance, or have other low-dose CT related concerns may benefit from blood testing for lung cancer.
9 Experts are featured in this series.
Related Content